Here are 1-2 brief analogies to describe Achieve Life Sciences (ACHV):

• Moderna for nicotine addiction treatment

• A specialized pharmaceutical company singularly focused on developing the next breakthrough drug for quitting smoking, akin to how a biotech might aim for the definitive treatment for a widespread condition like obesity.

• Cytisinicline: A plant-based alkaloid developed for smoking cessation and nicotine addiction by reducing the severity of nicotine withdrawal symptoms.

Achieve Life Sciences (ACHV) is a clinical-stage pharmaceutical company developing cytisinicline for smoking cessation and nicotine addiction. As such, its primary product is a prescription drug intended for direct human use.

Therefore, the company's product, once approved and commercialized, will primarily serve individuals. The categories of customers it would serve include:

1. Individuals seeking to quit smoking: This constitutes the core target demographic for cytisinicline, comprising people who are actively trying to cease tobacco use.
2. Individuals struggling with nicotine addiction: Beyond traditional cigarette smokers, this category includes users of various nicotine products (e.g., e-cigarettes, smokeless tobacco) who are dependent on nicotine and seeking therapeutic intervention.
3. Patients referred by healthcare professionals for smoking cessation: These are individuals whose need for smoking cessation treatment is identified and recommended by doctors, nurses, or other healthcare providers as part of a broader health management plan.

• Sopharma AD (SFA)

Richard Stewart, President and Chief Executive Officer. Mr. Stewart is a co-founder, President, and Chief Executive Officer of Achieve Life Sciences. He is also a founder and director of Ricanto Limited, a pharmaceutical asset optimization company. Mr. Stewart has served as Chairman and Chief Executive Officer of Renown Pharma Limited since 2016. Prior to Achieve, he was Chairman and CEO of Huxley Pharmaceuticals, Inc., which was acquired by BioMarin Pharmaceutical Inc.. He was also CEO of Brabant Pharma Limited, which was acquired by Zogenix Inc.. Additionally, Mr. Stewart co-founded and served as CEO of Amarin Corporation plc and co-founded and was CFO, and later Chief Business Officer, of SkyePharma plc.

Mark Oki, Chief Financial Officer. Mr. Oki joined Achieve Life Sciences as Chief Financial Officer on December 5, 2024. He has over 25 years of financial leadership experience in the biotechnology and pharmaceutical industries. Before joining Achieve, he served as CFO of Aytu Biopharma, Inc. from January 2022 until November 2024, and previously as CFO of Vivus LLC. His career also includes senior financial positions at Alexza Pharmaceuticals, Inc., Pharmacyclics, Inc., and Incyte Genomics, Inc.

Erik Atkisson, Chief Legal Officer. Erik Atkisson brings over 25 years of experience in the pharmaceutical and biotechnology industries to his role as Chief Legal Officer at Achieve Life Sciences. He possesses extensive expertise in guiding the global development, launch, and commercialization of biopharmaceutical products and has held senior legal positions at multiple clinical- and commercial-stage biopharmaceutical companies.

Craig Donnelly, Chief Operations Officer. Craig Donnelly is the Chief Operations Officer at Achieve Life Sciences. With over 25 years of experience in the biopharmaceutical industry, Mr. Donnelly has expertise in both technical development and regulatory CMC at all stages of development. He was previously the Executive Vice President, CMC and Regulatory CMC at Achieve.

Dr. Mark Rubinstein, Chief Medical Officer. Dr. Mark Rubinstein was promoted to permanent Chief Medical Officer in January 2026, after serving as Interim Chief Medical Officer since September 2025. He joined Achieve Life Sciences in October 2024 as Head of Medical Affairs. Previously, Dr. Rubinstein was the Head of Medical Affairs at Blip, where he led medical strategy for smoking and vaping cessation programs. He is also Professor Emeritus of Pediatrics at the University of California, San Francisco, where he conducted NIH-funded research on adolescent nicotine addiction and smoking cessation interventions for nearly 20 years.

Key Risks to Achieve Life Sciences (ACHV)

1. Regulatory Approval and Commercialization Challenges: The primary risk for Achieve Life Sciences revolves around the successful regulatory approval and subsequent commercialization of cytisinicline. While the company has seen promising clinical trial results and has a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026, for cytisinicline, regulatory approval by the FDA is not guaranteed. Delays or a rejection of the New Drug Application (NDA) could occur if the FDA requests additional data or studies, significantly impacting the company's projections and future. Even upon approval, the company faces substantial challenges in successfully launching and achieving market acceptance for cytisinicline, amidst competition and the complexities of the pharmaceutical market.
2. Heavy Pipeline Concentration and Dependence on a Single Product: Achieve Life Sciences is highly dependent on the success of cytisinicline, as it is the company's sole product candidate in late-stage development. This heavy pipeline concentration means that the company's future viability is almost entirely reliant on cytisinicline gaining regulatory approval and achieving commercial success. A failure in any stage of cytisinicline's development or commercialization would have a profound and potentially catastrophic impact on the business, as there are no other diverse revenue streams or product candidates to mitigate such a risk.
3. Financial Instability and Need for Additional Funding: As a clinical-stage pharmaceutical company with no current revenue, Achieve Life Sciences has reported substantial net losses and requires significant capital to fund its ongoing operations, clinical development, and eventual commercialization efforts. The company's cash runway extends into the second half of 2026, covering the FDA review period for cytisinicline. However, additional financing will likely be necessary for the commercial launch of the drug, which could lead to further shareholder dilution if new capital is raised through equity offerings.

The addressable markets for Achieve Life Sciences' main product, cytisinicline, for smoking cessation and nicotine addiction are substantial across various regions.

Global Market:

• The global smoking cessation and nicotine de-addiction market was valued at approximately USD 25.5 billion in 2024 and is projected to reach USD 77.8 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 12% from 2025 to 2034.
• Another estimate values the global smoking cessation and nicotine de-addiction market at USD 29.38 billion in 2024, expected to reach USD 92.41 billion by 2032, with a CAGR of 15.40%.
• A different report indicates the global smoking cessation and nicotine de-addiction market size was US$15.5 billion in 2025 and is projected to reach US$46.4 billion by 2036.
• The global nicotine addiction treatment market was valued at USD 65.93 billion in 2024 and is expected to reach USD 130.15 billion by 2032, growing at a CAGR of 10.2%.

North American Market:

• North America is a dominant region in the smoking cessation and nicotine de-addiction market, holding a 40.3% market share in 2023.
• The North America smoking cessation and nicotine de-addictions market size was valued at USD 74.27 billion in 2024 and is projected to reach USD 425.98 billion by 2032.

United States Market:

• Approximately 29 million adults in the United States smoke combustible cigarettes.
• There are also approximately 17 million adults in the United States who use e-cigarettes, with about 60% expressing a desire to quit.
• The Smoking Cessation and Nicotine Addiction Market size in the US was approximately USD 1,472 million in 2023, the highest among the 7 major markets.
• The U.S. smoking cessation aids market alone contributed USD 12.4 billion in 2025.
• The U.S. nicotine replacement therapy (NRT) market is projected to reach USD 1.34 billion by 2026.

Canadian Market:

• The Canada Nicotine Replacement Therapy (NRT) smoking cessation aids market size was valued at USD 205 million in 2025 and is estimated to reach USD 225 million by 2032.
• Approximately 4.5 million smokers reside in Canada.

United Kingdom Market:

• Over 5 million people smoke in England.
• The UK nicotine replacement therapy (NRT) market is projected to reach USD 0.2 billion by 2026.
• The UK was a significant contributor to Europe's smoking cessation aids market turnover in 2025.

Achieve Life Sciences (ACHV) is poised for significant future revenue growth over the next 2-3 years, primarily driven by the advancement and commercialization of its lead product candidate, cytisinicline. The key drivers are:

1. Successful Commercial Launch of Cytisinicline for Smoking Cessation in the United States: The most immediate and significant revenue driver is the anticipated FDA approval and subsequent commercial launch of cytisinicline for smoking cessation. The New Drug Application (NDA) was accepted by the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date of June 20, 2026. Achieve Life Sciences plans to launch the product commercially in late 2026, following potential approval. This launch is expected to address a significant unmet need, as it would be the first new FDA-approved smoking cessation pharmacotherapy in two decades, leveraging cytisinicline's differentiated efficacy and tolerability profile.
2. Expansion into the E-cigarette and Vaping Cessation Market: Achieve Life Sciences is also strategically positioned to enter the e-cigarette and vaping cessation market with cytisinicline. The company received a Commissioner's National Priority Voucher (CNPV) from the FDA for this indication, which has the potential to compress the FDA review timeline to 1-2 months once complete materials are submitted. Positive Phase 2 data (ORCA-V1) and an FDA agreement that a Phase 3 trial, combined with ORCA-V1, could support a supplemental NDA, pave a clear regulatory pathway for this indication. This represents a substantial and growing market with no currently FDA-approved treatments, offering a significant first-in-class opportunity.
3. Geographic Expansion Beyond the U.S.: While the initial focus for cytisinicline's launch will be the U.S. market, Achieve Life Sciences has stated its intent to develop and commercialize the drug in Canada and the United Kingdom. The company already holds license agreements with Sopharma AD and the University of Bristol. Successful market penetration and commercialization in the U.S. would likely facilitate and accelerate expansion efforts into these additional territories within the 2-3 year timeframe, contributing to broader revenue growth.
4. Market Penetration Driven by a Differentiated Product Profile: Cytisinicline is positioned to capture market share due to its promising effectiveness and favorable safety profile compared to existing treatments. As the first potential new pharmacotherapy for smoking cessation in two decades, and a potential first-in-class treatment for vaping cessation, its unique attributes are expected to drive adoption among healthcare providers and patients. The significant global burden of nicotine dependence and the lack of innovative treatment options create a substantial market opportunity for a differentiated product like cytisinicline.

Share Issuance

• Achieve Life Sciences' shares outstanding significantly increased from approximately 6.1 million as of March 11, 2021, to 53 million in Q3 2025, demonstrating substantial capital raises through equity offerings over the last three to five years.
• The company successfully closed a $45 million public offering to advance the development of cytisinicline for smoking cessation.

Inbound Investments

• Franklin Resources, Inc. and its affiliates held beneficial ownership of 6,369,193 shares, representing 11.5% of Achieve's common stock as of December 31, 2025, which includes shares issuable upon the exercise of warrants, indicating a notable institutional investment.

Capital Expenditures

• Achieve Life Sciences has shown an average Capital Expenditure (CapEx) percentage of revenue of 0% over the last three and five years, suggesting minimal to no significant capital expenditures.